Intuitive Surgical faces cautious Deutsche Bank view, shares stay under Nasdaq-100 pressure
Published on 06/23/2026 at 16:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 16:11.
Intuitive Surgical (US46120E6023) remains in focus on the NASDAQ-100 after Deutsche Bank reiterated a cautious stance with a Sell rating and a lower price target, according to recent analyst commentary based on Yahoo Finance data. Deutsche Bank note via Yahoo Finance The stock closed the last session at around 403 US dollars on Nasdaq, below several bullish long-term analyst targets. TradingKey closing data
What Deutsche Bank highlights
Deutsche Bank recently cut its price target on Intuitive Surgical from 440 to 366 US dollars and kept a Sell rating on the shares, as reported in a summary of the bank’s view. Intellectia.ai analyst summary The move reflects concerns about valuation after a strong multi-year run in robotic surgery and an environment of rising competition.
The bank’s stance contrasts with the broader U.S. medtech and life-science tools space, where several peers enjoy more balanced Buy-and-Hold distributions, but it underscores that even Nasdaq-100 constituents can face pockets of skepticism when earnings growth and pricing are scrutinized closely. Yahoo Finance hedge-risk discussion
How the consensus stacks up
Despite Deutsche Bank’s Sell, aggregated data place the average analyst price target for Intuitive Surgical shares near 565 US dollars, well above the roughly 403 US dollars where the stock most recently traded, according to one consensus overview. Consensus and forecast overview That implies substantial upside in many models, even after a muted performance in recent months.
Over the past month, Intuitive Surgical shares have delivered a negative return of around 8 percent and are down roughly 23 percent over twelve months, according to a hedge-fund letter cited by Yahoo Finance, showing that the stock has lagged the broader U.S. equity benchmarks despite its strong competitive position in robotic surgery. Yahoo Finance hedge-risk discussion
All news and analysis on the Intuitive Surgical shares
Further figures, estimates and ad-hoc disclosures on Intuitive Surgical can be found in the dedicated topic section and on the company’s investor-relations pages.
The business behind the stock
Intuitive Surgical earns most of its revenue from its da Vinci robotic-assisted surgical systems, consumable instruments and accessories, and related services installed in hospitals worldwide, according to its corporate information. Intuitive corporate overview The company has also been expanding its Ion endoluminal system for minimally invasive biopsy procedures in the lung.
Where the stock trades now
The Intuitive Surgical shares (US46120E6023) last closed on the NASDAQ at 402.89 US dollars on 2026-06-22, 16:00 ET, based on TradingKey data.
Key data on the Intuitive Surgical shares
- Company: Intuitive Surgical, Inc.
- ISIN: US46120E6023
- WKN: 888024
- Ticker: ISRG
- Trading venue: NASDAQ
- Price (as of 2026-06-22, 16:00): 402.89 USD
- Market cap: around 140 billion USD (as of 2026-06-22)
- Sector / industry: Health Care / Medical Devices
- Index membership: NASDAQ-100, S&P 500
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
